Truist lowered the firm’s price target on Integra LifeSciences to $39 from $41 and keeps a Hold rating on the shares. The analyst cites the company’s Q3 earnings miss and guidance cut, stating that while investor expectations were not high coming in, the incremental impacts from the Boston facility driving the miss and the ongoing uncertainty around the resolution of the issues will “keep shares range bound”.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IART:
- Integra LifeSciences price target lowered to $40 from $47 at Wells Fargo
- Integra LifeSciences sees Q4 adjusted EPS 89c-93c, consensus 92c
- Integra LifeSciences narrows FY23 EPS view to $3.10-$3.14 from $3.10-$3.18
- Integra LifeSciences reports Q3 adjusted EPS 76c, consensus 78c
- Integra LifeSciences Reports Third Quarter 2023 Financial Results
